OCUL - Ocular Therapeutix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.19
+0.01 (+0.17%)
As of 2:27PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close6.18
Open6.13
Bid6.16 x 900
Ask6.18 x 1000
Day's Range6.03 - 6.40
52 Week Range3.30 - 8.28
Volume247,900
Avg. Volume386,255
Market Cap238.897M
Beta (3Y Monthly)0.60
PE Ratio (TTM)N/A
EPS (TTM)-1.72
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.33
Trade prices are not sourced from all markets
  • MarketWatch6 hours ago

    Ocular Therapeutix stock drops 10% after FDA warning letter

    Ocular Therapeutix Inc. shares dropped 10% in Friday premarket trade after the company said it received a warning letter from the U.S. Food and Drug Administration relating to the company's "compliance with data collection and information reporting obligations" for a study. The reporting obligations are required as a condition for approval for the company's ReSure Sealant product, and Ocular Therapeutix is required to provide periodic reports to the FDA about the study. ReSure Sealant is approved in the U.S. to seal corneal incisions after cataract surgery. Ocular Therapeutix said it plans to respond to the warning letter within 15 days, as required, and is "committed to working with the FDA to address and resolve the concerns cited in the warning letter." Ocular shares have dropped nearly 4% over the last three months, compared with a 1.3% decline in the S&P 500 and a 1.3% rise in the Dow Jones Industrial Average .

  • Business Wire7 hours ago

    Ocular Therapeutix™ Receives FDA Warning Letter Related to ReSure® Sealant

    Ocular Therapeutix, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the receipt of a warning letter from the U.S. Food and Drug Administration (FDA) dated October 17, 2018 and received on October 18, 2018. The letter relates to Ocular’s compliance with data collection and information reporting obligations in a post-approval Device Exposure Registry study required as a condition for approval of the premarket approval (PMA) application for ReSure® Sealant. The Company is required to provide periodic reports to the FDA on the progress of this post-approval study until it is completed.

  • GlobeNewswireyesterday

    Investor Expectations to Drive Momentum within Teradata, Liberty TripAdvisor, CPI Card Group, Cara Therapeutics, Ocular Therapeutix, and G-III Apparel Group, LTD — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Simply Wall St.8 days ago

    Who Owns Ocular Therapeutix Inc (NASDAQ:OCUL)?

    A look at the shareholders of Ocular Therapeutix Inc (NASDAQ:OCUL) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge Read More...

  • Why Analysts See Solid Upside Potential for Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX), and AcelRx (ACRX)
    SmarterAnalyst9 days ago

    Why Analysts See Solid Upside Potential for Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX), and AcelRx (ACRX)

    On July 19, Ocular announced that the FDA had accepted its New Drug Application (NDA) for Dextenza for the treatment of ocular pain following ophthalmic surgery. The resubmission is considered a class 2 response and a Prescription Drug User Fee Act (PDUFA) has been set on December 28, 2018.

  • Business Wire23 days ago

    Ocular Therapeutix™ to Present at the 2018 Cantor Global Healthcare Conference

    Ocular Therapeutix, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will present at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 11:30 AM ET at the Intercontinental ...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of OCUL earnings conference call or presentation 7-Aug-18 8:30pm GMT

    Q2 2018 Ocular Therapeutix Inc Earnings Call

  • Here's Why Ocular Therapeutix Jumped 21.6% in August
    Motley Foollast month

    Here's Why Ocular Therapeutix Jumped 21.6% in August

    The company reported second-quarter 2018 financial results and an important business update.

  • Business Wire2 months ago

    Ocular Therapeutix™ to Present at the H.C. Wainwright 20th Annual Global Investment Conference

    Ocular Therapeutix, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will present at the H.C.

  • GlobeNewswire2 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Lindblad Expeditions, Milacron, Lantheus, RCI Hospitality, Ingles Markets, and Ocular Therapeutix — New Research Emphasizes Economic Growth

    NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lindblad ...

  • GuruFocus.com2 months ago

    Ocular Therapeutix Inc (OCUL) President & CEO Antony C. Mattessich Bought $119,000 of Shares

    President & CEO of Ocular Therapeutix Inc (NASDAQ:OCUL) Antony C. Mattessich bought 20,000 shares of OCUL on 08/20/2018 at an average price of $5.95 a share.

  • JMP Highlights Two Biotech Stocks to Consider Ahead of Upcoming FDA Decisions: Trevena (TRVN), Ocular (OCUL)
    SmarterAnalyst2 months ago

    JMP Highlights Two Biotech Stocks to Consider Ahead of Upcoming FDA Decisions: Trevena (TRVN), Ocular (OCUL)

    Both companies are due to have important FDA catalysts that could lead to a share price turnaround. Last year, Trevena (NASDAQ:TRVN) submitted a New Drug Application (NDA) for oliceridine, the first G protein biased ligand of the mu receptor designed to provide IV opioid pain relief with fewer side effects. The FDA will have an AdComm meeting before the PDUFA date on November 2, 2018. According to CEO Maxine Gowen, the company remains in active discussions for oliceridine licensing in the US as it gets closer to commercialization.

  • Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

    Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 0.00% and 85.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Ocular Therapeutix: 2Q Earnings Snapshot

    The Bedford, Massachusetts-based company said it had a loss of 37 cents per share. The biotechnology company posted revenue of $648,000 in the period. Ocular Therapeutix shares have increased 24 percent ...

  • Business Wire2 months ago

    Ocular Therapeutix™ Reports Second Quarter 2018 Financial Results and Business Update

    DEXTENZA® NDA Resubmission Submitted and Accepted by the U.S. Food and Drug Administration

  • Business Wire3 months ago

    Ocular Therapeutix™ To Report Second Quarter 2018 Financial Results

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter ended June 30, 2018 financial results on Tuesday, August 7, 2018. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Company’s financial results and provide a general business update. The live webcast can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com.

  • Business Wire3 months ago

    Ocular Therapeutix™ Announces FDA Acceptance of NDA Resubmission for DEXTENZA®

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has received acknowledgement from the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for DEXTENZA® has been received. DEXTENZA (dexamethasone insert) 0.4mg is Ocular Therapeutix’s lead product candidate for the treatment of ocular pain following ophthalmic surgery.

  • Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?
    Zacks3 months ago

    Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?

    Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?

  • Ocular Therapeutix (OCUL) Enters Oversold Territory
    Zacks3 months ago

    Ocular Therapeutix (OCUL) Enters Oversold Territory

    Ocular Therapeutix, Inc. (OCUL) has been on a bit of a cold streak lately

  • Business Wire4 months ago

    Ocular Therapeutix™ Announces NDA Resubmission of DEXTENZA™

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company’s New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate DEXTENZA™ (dexamethasone insert) 0.4mg, for the treatment of ocular pain following ophthalmic surgery. The resubmission is intended to address manufacturing deficiencies cited by the FDA in the Agency’s July 2017 Complete Response Letter.

  • Business Wire4 months ago

    Ocular Therapeutix™ to Present at the 2018 JMP Securities Life Sciences Conference

    Ocular Therapeutix, Inc. a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will present at the 2018 JMP Securities Life Sciences Conference on Wednesday, June 20, 2018 at 3:30 PM ET at the St.

  • 5 Clinical-Stage Biotech Stocks to Buy Under $10
    InvestorPlace5 months ago

    5 Clinical-Stage Biotech Stocks to Buy Under $10

    After all, the thrill of getting a big-time approval or even making through to the next round of FDA trail phases can send a biotech stock’s price surging. The key is in finding those smaller drug firms that have the ability to actually get through clinical trials and start marketing drugs. Likewise, spreading your money around to a variety of clinical stage names is also paramount if you want to play in the space.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of OCUL earnings conference call or presentation 8-May-18 8:30pm GMT

    Q1 2018 Ocular Therapeutix Inc Earnings Call

  • Associated Press5 months ago

    Ocular Therapeutix: 1Q Earnings Snapshot

    On a per-share basis, the Bedford, Massachusetts-based company said it had a loss of 40 cents. The biotechnology company posted revenue of $340,000 in the period. Ocular Therapeutix shares have increased ...